Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdV68-S
- Development stage
- Phase 1
- Lead developer
- Gritstone Oncology
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdV68-S is an investigational viral vector vaccine developed by Gritstone bio for the prevention of COVID-19. It utilizes a non-replicating chimpanzee adenovirus vector, ChAdV68, to deliver the genetic instructions for the SARS-CoV-2 spike protein. The use of a chimpanzee adenovirus is intended to circumvent the issue of pre-existing immunity to common human adenoviruses, which can limit vaccine effectiveness. ChAdV68-S is being evaluated in clinical trials, including those sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), as part of heterologous prime-boost vaccination strategies. In these regimens, it is often paired with self-amplifying mRNA (SAM) vaccines to elicit a robust and durable immune response, characterized by both high titers of neutralizing antibodies and potent T-cell activation.
- Other names
- ChAdV68-SARS-CoV-2-SChAdV-68-SARS-CoV-2-SChAdV 68-SARS-CoV-2-SChimpanzee Adenovirus 68-Spike vaccineChAd-S
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on ChAdV68-S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdV68-S.